Trial Profile

Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semagacestat (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Therapeutic Use
Acronyms IDENTITY-XT
Sponsors Eli Lilly and Company

Most Recent Events

02 Aug 2011 Status changed from active, no longer recruiting to completed.
17 Dec 2010 Primary endpoint changed from difference in vital signs to changes from baseline in Alzheimer's Disease Assessment Scale - Cognitive subscale and Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory in ClinicalTrials.gov record.
17 Dec 2010 Planned End Date changed from 1 Jan 2014 to 1 Apr 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com